{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:50:14Z","timestamp":1782172214198,"version":"3.54.5"},"reference-count":247,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1097\/ftd.0b013e31827c11e7","type":"journal-article","created":{"date-parts":[[2013,1,3]],"date-time":"2013-01-03T13:54:57Z","timestamp":1357221297000},"page":"4-29","source":"Crossref","is-referenced-by-count":175,"title":["Therapeutic Drug Monitoring of Antiepileptic Drugs by Use of Saliva"],"prefix":"10.1097","volume":"35","author":[{"given":"Philip N.","family":"Patsalos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave J.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210129","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":". Antiepileptic drugsbest practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies.","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"R2-2-20210129","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00007691-200306000-00016","article-title":". Therapeutic drug monitoring of the newer antiepileptic drugs.","volume":"25","author":"Johannessen","year":"2003","journal-title":"Ther Drug Monit"},{"key":"R3-2-20210129","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.3390\/ph3061909","article-title":"Therapeutic drug monitoring of the newer anti-epilepsy medications.","volume":"3","author":"Krasowski","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"key":"R4-2-20210129","first-page":"161","article-title":"Therapeutic drug monitoring of newer antiepileptic drugs.","volume":"35","author":"Brandt","year":"2011","journal-title":"J Lab Med"},{"key":"R5-2-20210129","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":". AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011.","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"R6-2-20210129","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1177\/000456329903600102","article-title":"New antiepileptic drugs.","volume":"36","author":"Patsalos","year":"1999","journal-title":"Ann Clin Biochem"},{"key":"R7-2-20210129","first-page":"1373","article-title":"Evaluation of methods to determine protein-binding of drugs: equilibrium dialysis, ultracentrifugation, gel filtration.","volume":"27","author":"Kurz","year":"1977","journal-title":"Drug Res"},{"issue":"supp 1","key":"R8-2-20210129","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2165\/00003088-198400091-00008","article-title":"The EMIT ultrafiltration technique compared with equilibrium dialysis and ultra-centrifugation to determine protein binding of phenytoin.","volume":"9","author":"Oellerich","year":"1984","journal-title":"Clin Pharmacokinet"},{"key":"R9-2-20210129","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/clinchem\/31.1.60","article-title":". Equilibrium dialysis, ultrafiltration and ultracentrifugation compared for determining the plasma protein binding characteristics of valproic acid.","volume":"30","author":"Barre","year":"1985","journal-title":"Clin Chem"},{"key":"R10-2-20210129","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/FTD.0b013e31819e91ce","article-title":"Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls.","volume":"31","author":"Edelbroek","year":"2009","journal-title":"Ther Drug Monit"},{"key":"R11-2-20210129","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/000456328402100615","article-title":". A phenytoin assay using dried blood spot samples suitable for domiciliary therapeutic drug monitoring.","volume":"21","author":"Coombes","year":"1984","journal-title":"Ann Clin Biochem"},{"key":"R12-2-20210129","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jpba.2008.09.025","article-title":". Rapid assay of topiramate in dried blood spots by a new liquid chromatography-tandem mass spectrometric method.","volume":"48","author":"la Marca","year":"2008","journal-title":"J Pharm Biomed Anal"},{"key":"R13-2-20210129","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1111\/j.1528-1167.2009.02204.x","article-title":". A new rapid micromethod for the assay of phenobarbital from dried blood spots by LC-tandem mass spectrometry.","volume":"50","author":"la Marca","year":"2009","journal-title":"Epilepsia"},{"key":"R14-2-20210129","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jpba.2010.07.015","article-title":". Rapid assay of rufinamide in dried blood spots by a new liquid chromatography-tandem mass spectrometric method.","volume":"54","author":"la Marca","year":"2011","journal-title":"J Pharm Biomed Anal"},{"key":"R15-2-20210129","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1111\/j.1528-1167.2010.02771.x","article-title":". Drug monitoring of lamotrigine and oxcarbazepine combination during pregnancy.","volume":"51","author":"Wegner","year":"2010","journal-title":"Epilepsia"},{"key":"R16-2-20210129","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00216-010-4048-2","article-title":"Dried plasma spots as an alternative sample collection technique for the quantitative LC-MSMS determination of gabapentin.","volume":"398","author":"Kolocouri","year":"2010","journal-title":"Anal Bioanal Chem"},{"key":"R17-2-20210129","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/ana.410040211","article-title":". Greater reliability of tear versus saliva anticonvulsant levels.","volume":"4","author":"Tondi","year":"1978","journal-title":"Ann Neurol"},{"key":"R18-2-20210129","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1528-1157.1979.tb04854.x","article-title":". Tears as the best practical indicator of the unbound fraction of an anticonvulsant drug.","volume":"20","author":"Monaco","year":"1979","journal-title":"Epilepsia"},{"key":"R19-2-20210129","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1528-1157.1981.tb04100.x","article-title":". Diphenylhydantoin and primidone in tears.","volume":"22","author":"Monaco","year":"1981","journal-title":"Epilepsia"},{"key":"R20-2-20210129","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1528-1157.1982.tb05049.x","article-title":". The free fraction of valproic acid in tears, saliva, and cerebrospinal fluid.","volume":"23","author":"Monaco","year":"1982","journal-title":"Epilepsia"},{"key":"R21-2-20210129","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00007691-198104000-00001","article-title":"Ethosuximide in tears, saliva and cerebral fluid.","volume":"3","author":"Piredda","year":"1981","journal-title":"Ther Drug Monit"},{"key":"R22-2-20210129","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/00007691-200012000-00011","article-title":". Assessment of drug concentration in tears in therapeutic drug monitoring I: determination of valproic acid in tears by gas chromatographymass spectrometry with ECNCI mode.","volume":"22","author":"Nakajima","year":"2000","journal-title":"Ther Drug Monit"},{"key":"R23-2-20210129","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1600-0404.1978.tb02879.x","article-title":". Excretion of antiepileptic drugs in sweat.","volume":"58","author":"Parnas","year":"1978","journal-title":"Acta Neurol Scand"},{"key":"R24-2-20210129","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/jat\/20.3.197","article-title":". Detection of codeine and phenobarbital in sweat collected with a sweat patch.","volume":"20","author":"Kintz","year":"1996","journal-title":"J Anal Toxicol"},{"key":"R25-2-20210129","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1528-1157.1975.tb06051.x","article-title":"Anticonvulsant levels in saliva, serum and cerebrospinal fluid.","volume":"16","author":"Troupin","year":"1975","journal-title":"Epilepsia"},{"key":"R26-2-20210129","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1528-1157.1975.tb04758.x","article-title":"Diphenylhydantoin, phenobarbital and primidone in saliva, plasma, and cerebrospinal fluid.","volume":"16","author":"Schmidt","year":"1975","journal-title":"Epilepsia"},{"key":"R27-2-20210129","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1365-2125.1976.tb04878.x","article-title":". CSF concentrations and serum protein binding of carbamazepine and carbamazepine-10,11-epoxide in epileptic patients.","volume":"3","author":"Johannessen","year":"1976","journal-title":"Br J Clin Pharmacol"},{"key":"R28-2-20210129","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/0920-1211(91)90028-E","article-title":"Comparison of valproate concentrations in human plasma, CSF and brain tissue after administration of different formulations of valproate or valpromide.","volume":"9","author":"Weiser","year":"1991","journal-title":"Epilepsy Res"},{"key":"R29-2-20210129","doi-asserted-by":"crossref","first-page":"87S","DOI":"10.1111\/j.1365-2125.1989.tb03467.x","article-title":". Cerebrospinal fluid GABA and seizure control with vigabatrin.","volume":"27","author":"Riekkinen","year":"1989","journal-title":"Br J Clin Pharmacol"},{"key":"R30-2-20210129","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0920-1211(92)90020-T","article-title":"Selected CSF biochemistry and gabapentin concentrations in the CSF and plasma in patients with partial seizures after a single oral dose of gabapentin.","volume":"11","author":"Ben-Menachem","year":"1992","journal-title":"Epilepsy Res"},{"key":"R31-2-20210129","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0920-1211(95)00026-7","article-title":". Seizure frequency and CSF parameters in a double-blind placebo controlled trial of gabapentin in patients with intractable complex paryial seizures.","volume":"21","author":"Ben-Menachem","year":"1995","journal-title":"Epilepsy Res"},{"key":"R32-2-20210129","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1528-1167.2006.00504.x","article-title":". Comparison of brain extracellular fluid, brain tissue, cerebral fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy.","volume":"47","author":"Rambeck","year":"2006","journal-title":"Epilepsia"},{"key":"R35-2-20210129","first-page":"812","article-title":"Testing human hair for carbamazepine in epileptic patients: is hair investigation suitable for drug monitoring Hum Exp Toxicol.","volume":"14","author":"Kintz","year":"1995","journal-title":""},{"key":"R36-2-20210129","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/00912709922007561","article-title":". Carbamazepine levels in head hair of patients under long-term treatment: a method to evaluate the history of drug use.","volume":"39","author":"Psillakis","year":"1999","journal-title":"J Clin Pharm"},{"key":"R37-2-20210129","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1472-6904-1-2","article-title":". The concentration of three anti-seizure medications in hair: the effects of hair color, controlling of dose and age.","volume":"1","author":"Mieczkowski","year":"2001","journal-title":"BMC Clin Pharmacol"},{"key":"R38-2-20210129","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1046\/j.1528-1157.2002.38601.x","article-title":". Self-discontinuation of antiepileptic medication in pregnancy: detection by hair analysis.","volume":"43","author":"Williams","year":"2002","journal-title":"Epilepsia"},{"key":"R39-2-20210129","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jchromb.2005.02.004","article-title":"Determination of oxcarbazepine and its metabolites in postmortem blood and hair by means of liquid chromatography with mass detection (HPLCAPCIMS).","volume":"825","author":"Klys","year":"2005","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R40-2-20210129","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0379-0738(96)02053-1","article-title":"Hair analysis as a potential index of therapeutic compliance in the treatment of epilepsy.","volume":"84","author":"Williams, Patsalos","year":"1997","journal-title":"Forensic Sci Int"},{"key":"R41-2-20210129","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00007691-200102000-00004","article-title":". Relationship between dosage of carbamazepine and concentration in hair and plasma samples from a compliant inpatient epileptic population.","volume":"23","author":"Williams","year":"2001","journal-title":"Ther Drug Monit"},{"key":"R42-2-20210129","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.pediatrneurol.2003.12.017","article-title":". Hair analysis differentiates chronic from acute carbamazepine intoxication.","volume":"31","author":"Mantzouranis","year":"2004","journal-title":"Pediatr Neurol"},{"key":"R43-2-20210129","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/00003088-197803010-00003","article-title":"Therapeutic drug monitoring in saliva.","volume":"3","author":"Danhof","year":"1978","journal-title":"Clin Pharmacokinet"},{"key":"R44-2-20210129","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00007691-198208000-00001","article-title":"The use of saliva in therapeutic drug monitoring.","volume":"4","author":"Mucklow","year":"1982","journal-title":"Ther Drug Monit"},{"key":"R45-2-20210129","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/00003088-199223050-00003","article-title":"Therapeutic drug monitoring in saliva. An update.","volume":"23","author":"Drobitch","year":"1992","journal-title":"Clin Pharmacokinet"},{"key":"R46-2-20210129","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00003088-199936060-00006","article-title":"Therapeutic drug concentration monitoring using saliva samples: focus on anticonvulsants.","volume":"36","author":"Liu","year":"1999","journal-title":"Clin Pharmacokin"},{"key":"R47-2-20210129","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/0897190007305139","article-title":"Salivary monitoring of antiepileptic drugs.","volume":"20","author":"Baumann","year":"2007","journal-title":"J Pharm Pract"},{"key":"R48-2-20210129","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1365-2125.1982.tb01431.x","article-title":"Saliva carbamazepine levels in children before and during multiple dosing.","volume":"13","author":"Moreland","year":"1982","journal-title":"Br J Clin Pharmacol"},{"key":"R49-2-20210129","first-page":"27","article-title":"Comparative study of the levels of anticonvulsants and their free fractions in venous blood, saliva and capillary blood in man.","volume":"15","author":"Van","year":"1984","journal-title":"J Pharmacol"},{"key":"R50-2-20210129","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00007691-198403000-00008","article-title":"The place of saliva in antiepileptic drug monitoring.","volume":"6","author":"Knott","year":"1984","journal-title":"Ther Drug Monit"},{"key":"R51-2-20210129","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1469-8749.1986.tb03922.x","article-title":"A study on carbamazepine levels, including estimation of 10-11 epoxy-carbamazepine and levels in free plasma and saliva.","volume":"28","author":"Tomlin","year":"1986","journal-title":"Dev Med Child Neurol"},{"key":"R52-2-20210129","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/088307389000500219","article-title":". Diurnal variation of carbamazepine and carbamazepine-10,11-epoxide in plasma and saliva in children with epilepsy: a comparison between conventional and slow-release formulations.","volume":"5","author":"Eeg-Olofsson","year":"1990","journal-title":"J Child Neurol"},{"key":"R53-2-20210129","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/00007691-199009000-00016","article-title":". Evaluation of the Ames Seralyzer for the determination of carbamazepine, phenobarbital, and phenytoin in saliva.","volume":"12","author":"Miles","year":"1990","journal-title":"Ther Drug Monit"},{"key":"R54-2-20210129","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/00007691-199712000-00006","article-title":". Is saliva suitable for therapeutic monitoring of anticonvulsants in children: an evaluation in the routine clinical setting.","volume":"19","author":"Gorodischer","year":"1997","journal-title":"Ther Drug Monit"},{"key":"R55-2-20210129","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0387-7604(12)80025-8","article-title":". Monitoring of concentrations of clobazam and norclobazam in serum and saliva of children with epilepsy.","volume":"13","author":"Bardy","year":"1991","journal-title":"Brain Dev"},{"key":"R56-2-20210129","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1212\/WNL.27.5.409","article-title":". Salivary levels of anticonvulsants: a practical approach to drug monitoring.","volume":"27","author":"McAuliffe","year":"1977","journal-title":"Neurology"},{"key":"R57-2-20210129","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/clinchem\/23.2.157","article-title":". Use of saliva for therapeutic drug monitoring.","volume":"23","author":"Horning","year":"1977","journal-title":"Clin Chem"},{"key":"R58-2-20210129","first-page":"546","article-title":". Single sample estimate of ethosuximide clearance.","volume":"24","author":"Bachmann","year":"1986","journal-title":"Int J Clin Ther Toxicol"},{"key":"R59-2-20210129","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/j.1528-1157.1997.tb01204.x","article-title":". Oral gabapentin disposition in patients with epilepsy after a high-protein diet.","volume":"38","author":"Benetello","year":"1997","journal-title":"Epilepsia"},{"key":"R60-2-20210129","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S1059131102001425","article-title":". The absorption of gabapentin following high dose escalation.","volume":"12","author":"Berry","year":"2003","journal-title":"Seizure"},{"key":"R61-2-20210129","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1528-1167.2010.02751.x","article-title":". Saliva and serum lacosamide concentrations in patients with epilepsy.","volume":"52","author":"Greenaway","year":"2011","journal-title":"Epilepsia"},{"key":"R62-2-20210129","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/00007691-200010000-00003","article-title":"Saliva and serum concentration of lamotrigine in patients with epilepsy.","volume":"22","author":"Tsiropoulos","year":"2000","journal-title":"Ther Drug Monit"},{"key":"R63-2-20210129","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1592\/phco.23.15.1550.31957","article-title":". Correlation of lamotrigine concentrations between serum and saliva.","volume":"23","author":"Ryan","year":"2003","journal-title":"Pharmacotherapy"},{"key":"R64-2-20210129","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.jocn.2005.12.037","article-title":". Monitoring salivary lamotrigine concentrations.","volume":"13","author":"Malone","year":"2006","journal-title":"J Clin Neurosci"},{"key":"R65-2-20210129","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00007691-200302000-00009","article-title":". Correlation of levetiracetam concentrations between serum and saliva.","volume":"25","author":"Grim","year":"2003","journal-title":"Ther Drug Monit"},{"key":"R66-2-20210129","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5414\/CPP45047","article-title":". Comparison of plasma and saliva concentrations of levetiracetam following administration orally as a tablet and as a solution in healthy adult volunteers.","volume":"45","author":"Lins","year":"2007","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R67-2-20210129","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/FTD.0b013e3180683d55","article-title":". Saliva and serum levetiracetam concentrations in patients with epilepsy.","volume":"29","author":"Mecarelli","year":"2007","journal-title":"Ther Drug Monit"},{"key":"R68-2-20210129","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/BF00609629","article-title":"Disposition of the anti-epileptic oxcarbazepine and its metabolites in healthy volunteers.","volume":"22","author":"Thiesohn","year":"1982","journal-title":"Eur J Clin Pharmacol"},{"key":"R69-2-20210129","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1600-0404.1983.tb05340.x","article-title":". Pharmacokinetics of 10-OH-carbazepine, the main metabolite of the antiepileptic oxcarbazepine from serum and saliva concentrations.","volume":"68","author":"Kristensen","year":"1983","journal-title":"Acta Neurol Scand"},{"key":"R70-2-20210129","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF00870993","article-title":"Use of saliva for monitoring oxcarbazepine therapy in epileptic patients.","volume":"31","author":"Klitgaard","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"key":"R71-2-20210129","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/bdd.2510160708","article-title":". Comparison of plasma and saliva concentrations of the active monohydroxy metabolite of oxcarbazepine in patients at steady state.","volume":"16","author":"Cardot","year":"1995","journal-title":"Biopharm Drug Dispos"},{"key":"R72-2-20210129","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00007691-200406000-00014","article-title":". Feasibility and limitations of oxcarbazepine monitoring using salivary monohydroxycarbamazepine (MHD).","volume":"26","author":"Miles","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R73-2-20210129","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00007691-198102000-00006","article-title":"Salivary anticonvulsant levels in children: a comparison of methods.","volume":"3","author":"Goldsmith","year":"1981","journal-title":"Ther Drug Monit"},{"key":"R74-2-20210129","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00007691-198204000-00009","article-title":"Phenobarbital pharmacokinetics and salivary and serum concentrations in pregnancy.","volume":"4","author":"Luoma","year":"1982","journal-title":"Ther Drug Monit"},{"key":"R75-2-20210129","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/BF00439247","article-title":". Correlation between the saliva and free serum concentration of phenobarbitone in epileptic children.","volume":"145","author":"Tokugawa","year":"1986","journal-title":"Eur J Pediatr"},{"key":"R76-2-20210129","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2125.1984.tb05015.x","article-title":". Effect of valproate on free plasma phenytoin concentrations.","volume":"18","author":"Tsanaclis","year":"1984","journal-title":"Br J Clin Pharmacol"},{"key":"R77-2-20210129","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00216-011-5126-9","article-title":". Development and validation of an HPLC-UV detection assay for the determination of rufinamide in human plasma and saliva.","volume":"401","author":"Mazzucchelli","year":"2011","journal-title":"Anal Bioanal Chem"},{"key":"R78-2-20210129","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0887-8994(03)00048-1","article-title":". Topiramate concentration in saliva: an alternative to serum monitoring.","volume":"29","author":"Miles","year":"2003","journal-title":"Pediatr Neurol"},{"key":"R79-2-20210129","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0090-9556(25)07404-5","article-title":"Pharmacokinetics and metabolism of vigabatrin following a single oral dose of 14Cvigabatrin in healthy male volunteers.","volume":"21","author":"Durham","year":"1993","journal-title":"Drug Metab Dispos"},{"key":"R80-2-20210129","first-page":"291","article-title":". Concentrations of zonisamide in serum, free fraction, mixed saliva and cerebrospinal fluid in epileptic children treated with monotherapy.","volume":"47","author":"Kumagai","year":"1993","journal-title":"Jpn J Psychiatry Neurol"},{"key":"R81-2-20210129","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF00561556","article-title":". Distribution and elimination kinetics of carbamazepine in man.","volume":"8","author":"Rawlins","year":"1975","journal-title":"Eur J Clin Pharmacol"},{"key":"R82-2-20210129","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1365-2125.1992.tb04089.x","article-title":". Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites.","volume":"33","author":"Kudriakova","year":"1992","journal-title":"Br J Clin Pharmacol"},{"key":"R83-2-20210129","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2165\/00003088-198510010-00004","article-title":". Carbamazepine metabolism in man: induction and pharmacogenetic aspects.","volume":"10","author":"Eichelbaum","year":"1985","journal-title":"Clin Pharmacokinet"},{"key":"R84-2-20210129","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S0140-6736(77)92098-0","article-title":". Salivary carbamazepine concentrations.","volume":"1","author":"Chambers","year":"1977","journal-title":"Lancet"},{"key":"R85-2-20210129","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF00443121","article-title":"Use of saliva in monitoring carbamazepine medication in epileptic children.","volume":"126","author":"Bartels","year":"1977","journal-title":"Eur J Pediat"},{"key":"R86-2-20210129","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/cpt1978233320","article-title":"Kinetics of carbamazepine and carbamazepine-epoxide, determined by use of plasma and saliva.","volume":"23","author":"Westenberg","year":"1978","journal-title":"Clin Pharmacol Ther"},{"key":"R87-2-20210129","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/clpt.1980.223","article-title":"Concentrations and kinetics of carbamazepine in whole saliva, parotid saliva, serum ultrafiltrate, and serum.","volume":"28","author":"Paxton","year":"1980","journal-title":"Clin Pharmacol Ther"},{"key":"R88-2-20210129","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1600-0404.1980.tb01503.x","article-title":"Value of saliva samples in monitoring carbamazepine concentrations in epileptic patients.","volume":"61","author":"Kristensen","year":"1980","journal-title":"Acta Neurol Scand"},{"key":"R89-2-20210129","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2125.1981.tb01851.x","article-title":"Salivary concentration and plasma protein binding of carbamazepine and carbamazepine-10,11-epoxide in epileptic patients.","volume":"12","author":"MacKichan","year":"1981","journal-title":"Br J Clin Pharmacol"},{"key":"R90-2-20210129","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1136\/adc.56.8.637","article-title":"Saliva carbamazepine and phenytoin level monitoring.","volume":"56","author":"Rylance","year":"1981","journal-title":"Arch Dis Child"},{"key":"R91-2-20210129","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/00007691-199103000-00013","article-title":"Interindividual variability of carbamazepine, phenobarbital, and phenytoin concentrations in saliva.","volume":"13","author":"Miles","year":"1991","journal-title":"Ther Drug Monit"},{"key":"R92-2-20210129","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2125.1993.tb05700.x","article-title":". A simple collection method for saliva in children: potential for home monitoring of carbamazepine therapy.","volume":"35","author":"Chee","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"R93-2-20210129","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1528-1157.1995.tb01668.x","article-title":". Use of saliva in home monitoring of carbamazepine levels.","volume":"36","author":"Rosenthal","year":"1995","journal-title":"Epilepsia"},{"key":"R94-2-20210129","first-page":"60","article-title":"Correlation of serum and salivary carbamazepine concentration in epileptic patients: implications for therapeutic drug monitoring.","volume":"50","author":"Vasudev","year":"2002","journal-title":"Neurol India"},{"key":"R95-2-20210129","first-page":"19","article-title":"Salivary free concentrations of anti-epileptic drugs: an evaluation in routine clinical setting.","volume":"103","author":"Al Zaabi","year":"2003","journal-title":"Acta Neurol Belg"},{"issue":"suppl 1","key":"R96-2-20210129","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/ddr.430010716","article-title":"Aspects of the pharmacokinetics and pharmacodynamics of benzodiazepines with particular reference to clobazam.","volume":"2","author":"Aucamp","year":"1982","journal-title":"Drug Dev Res"},{"key":"R97-2-20210129","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/jps.2600630407","article-title":". Pharmacokinetic profile of clonazepam in dog and humans and of flunitrazepam in dog.","volume":"63","author":"Kaplan","year":"1974","journal-title":"J Pharm Sci"},{"key":"R98-2-20210129","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF00614012","article-title":"Pharmacokinetics of the anticonvulsant drug clonazepam evaluated from single oral and intravenous doses and repeated oral administration.","volume":"9","author":"Berlin","year":"1975","journal-title":"Eur J Clin Pharmacol"},{"key":"R99-2-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00007691-199602000-00001","article-title":"Clonazepam disposition in pediatric patients.","volume":"18","author":"Walson","year":"1996","journal-title":"Ther Drug Monit"},{"key":"R100-2-20210129","first-page":"21","article-title":"The stability of benzodiazepines in saliva.","volume":"10","author":"Hart","year":"1988","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"R101-2-20210129","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1177\/0091270004267591","article-title":"Safety, tolerability, and pharmacokinetics profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans.","volume":"44","author":"Almeida","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"R102-2-20210129","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1517\/14656566.2012.667803","article-title":"Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate.","volume":"13","author":"Patsalos","year":"2012","journal-title":"Exp Opin Pharmacother"},{"key":"R103-2-20210129","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1586\/ern.09.136","article-title":"Drug interactions involving the new second- and third-generation antiepileptic drugs.","volume":"10","author":"Johannessen Landmark","year":"2010","journal-title":"Expert Rev Neurother"},{"key":"R104-2-20210129","first-page":"213","article-title":"The absorption and excretion of ethosuximide.","volume":"7","author":"Buchanan","year":"1973","journal-title":"Int J Clin Pharmacol"},{"key":"R105-2-20210129","first-page":"172","article-title":". Pharmacokinetics of drugs used for petit mal absence epilepsy.","volume":"14","author":"Eadie","year":"1977","journal-title":"Clin Exp Neurol"},{"key":"R106-2-20210129","first-page":"642","article-title":". Evaluation of the elimination of (14C) felbamate in healthy men.","volume":"31","author":"Shumaker","year":"1990","journal-title":"Epilepsia"},{"key":"R107-2-20210129","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1528-1157.1999.tb00777.x","article-title":". Quantification in patient urine samples of felbamate and three metabolites: acid carbamate and two mercapturic acids.","volume":"40","author":"Thompson","year":"1999","journal-title":"Epilepsia"},{"key":"R108-2-20210129","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1528-1157.1991.tb04669.x","article-title":". Discontinuation of phenytoin and carbamazepine in patients receiving felbamate.","volume":"32","author":"Wagner","year":"1991","journal-title":"Epilepsia"},{"issue":"suppl 3","key":"R109-2-20210129","first-page":"84","article-title":". Effect of felbamate on carbamazepine pharmacokinetics.","volume":"33","author":"Howard","year":"1992","journal-title":"Epilepsia"},{"issue":"suppl 3","key":"R110-2-20210129","first-page":"8","article-title":". Felbamate steady-state pharmaco-kinetics during co-administration of valproate.","volume":"32","author":"Ward","year":"1991","journal-title":"Epilepsia"},{"key":"R111-2-20210129","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-1211(00)00117-0","article-title":". Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability.","volume":"40","author":"Gidal","year":"2000","journal-title":"Epilepsy Res"},{"key":"R112-2-20210129","first-page":"830","article-title":"Pharmacokinetics and metabolism of gabapentin in rat, dog and man.","volume":"36","author":"Vollmer","year":"1986","journal-title":"Azneimittelforschung"},{"issue":"suppl florence","key":"R113-2-20210129","first-page":"147","article-title":". Serum gabapentin levels continue to increase with dose in the high-range in children and teenagers.","volume":"41","author":"Besag","year":"2000","journal-title":"Epilepsia"},{"issue":"suppl 7","key":"R114-2-20210129","first-page":"144","article-title":". Salivary monitoring of lamotrigine and gabapentin.","volume":"40","author":"Tennison","year":"1999","journal-title":"Epilepsia"},{"key":"R115-2-20210129","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.nurt.2006.10.002","article-title":". Lacosamide.","volume":"5","author":"Doty","year":"2007","journal-title":"Neurotherapeutics"},{"key":"R117-2-20210129","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2165\/00003088-199325060-00003","article-title":"Lamotrigine clinical pharmacokinetics.","volume":"5","author":"Rambeck","year":"1993","journal-title":"Clin Pharmacokinet"},{"key":"R118-2-20210129","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1517\/17425255.2.6.1009","article-title":"Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy.","volume":"2","author":"Biton","year":"2006","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R119-2-20210129","first-page":"211","article-title":". Pharmacokinetics of lamotrigine (Lamictal) in plasma and saliva.","volume":"3","author":"Trnavska","year":"1991","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"R120-2-20210129","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2125.1985.tb05120.x","article-title":". Lamotrigine (BW430C), a potential anticonvulsant. Effects on the central nervous system in comparison with phenytoin and diazepam.","volume":"20","author":"Cohen","year":"1985","journal-title":"Br J Clin Pharmacol"},{"key":"R121-2-20210129","first-page":"517","article-title":"Comparison of plasma and saliva concentrations of lamotrigine in healthy volunteers.","volume":"57","author":"Incecayir","year":"2007","journal-title":"Arzneimittelforschung"},{"key":"R122-2-20210129","first-page":"599","article-title":". A sensitive and selective HPLC method for estimation of lamotrigine in human plasma and saliva: application to plasma-saliva correlation in epileptic patients.","volume":"60","author":"Mallayasamy","year":"2010","journal-title":"Arzneimittelforschung"},{"key":"R123-2-20210129","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0163-7258(99)00052-2","article-title":"Pharmacokinetic profile of levetiracetam: toward ideal characteristics.","volume":"85","author":"Patsalos","year":"2000","journal-title":"Pharmacol Ther"},{"key":"R124-2-20210129","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2165\/00003088-200443110-00002","article-title":"Clinical pharmacokinetics of levetiracetam.","volume":"43","author":"Patsalos","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"R125-2-20210129","first-page":"1","article-title":"Levetiracetam: pharmacology and therapeutics in the treatment of epilepsy and other neurological conditions.","volume":"13","author":"Patsalos","year":"2004","journal-title":"Rev Contemp Pharmacother"},{"key":"R126-2-20210129","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1111\/j.1528-1167.2006.00819.x","article-title":". In situ metabolism of levetiracetam in blood of patients with epilepsy.","volume":"47","author":"Patsalos","year":"2006","journal-title":"Epilepsia"},{"key":"R127-2-20210129","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/cp.1999.v66.103170001","article-title":". Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects.","volume":"66","author":"Volosov","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"R128-2-20210129","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/00023210-200115020-00005","article-title":"Oxcarbazepine-an update of its efficacy in the management of epilepsy.","volume":"15","author":"Wellington","year":"2001","journal-title":"CNS Drugs"},{"key":"R129-2-20210129","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/BF00315422","article-title":"Protein binding of oxcarbazepine and its primary active metabolite, 10-hydroxycarbazepine, in patients with trigeminal neuralgia.","volume":"39","author":"Patsalos","year":"1990","journal-title":"Eur J Clin Pharmacol"},{"key":"R130-2-20210129","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2125.1994.tb04234.x","article-title":". A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients.","volume":"37","author":"McKee","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"R131-2-20210129","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2165\/00003088-200342120-00002","article-title":"Clinical pharmacokinetics of oxcarbazepine.","volume":"42","author":"May","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"R132-2-20210129","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/j.1552-4604.1982.tb02662.x","article-title":". Phenobarbital pharmacokinetics and bioavailability in adults.","volume":"22","author":"Nelson","year":"1982","journal-title":"J Clin Pharmacol"},{"key":"R133-2-20210129","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF01061382","article-title":". Kinetics of phenobarbital in normal subjects and epileptic patients.","volume":"23","author":"Wilensky","year":"1982","journal-title":"Eur J Clin Pharmacol"},{"key":"R134-2-20210129","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/cpt1975186742","article-title":". Phenytoin and phenobarbital concentrations in saliva and plasma measured by radioimmunoassay.","volume":"18","author":"Cook","year":"1975","journal-title":"Clin Pharmacol Ther"},{"key":"R135-2-20210129","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/cpt1978245563","article-title":". Drug concentration in saliva.","volume":"24","author":"Mucklow","year":"1978","journal-title":"Clin Pharmacol Ther"},{"key":"R136-2-20210129","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1528-1157.1979.tb04774.x","article-title":". Estimation of plasma unbound phenobarbital concentration by using mixed saliva.","volume":"20","author":"Nishihara","year":"1979","journal-title":"Epilepsia"},{"key":"R137-2-20210129","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0022-3476(81)80786-X","article-title":". Saliva phenobarbital and phenytoin concentrations in epileptic adolescents.","volume":"98","author":"Friedman","year":"1981","journal-title":"J Pediatr"},{"key":"R138-2-20210129","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0920-1211(90)90090-I","article-title":"Possible roles for frequent salivary antiepileptic drug monitoring in the management of epilepsy.","volume":"6","author":"Herkes","year":"1990","journal-title":"Epilepsy Res"},{"key":"R139-2-20210129","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/00003088-197904020-00002","article-title":"Bioavailability of phenytoin: clinical pharmacokinetic and therapeutic implications.","volume":"4","author":"Neurvonen","year":"1979","journal-title":"Clin Pharmacokinet"},{"key":"R140-2-20210129","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2165\/00003088-197904030-00001","article-title":"Clinical pharmacokinetics of phenytoin.","volume":"4","author":"Richens","year":"1979","journal-title":"Clin Pharmacokinet"},{"key":"R141-2-20210129","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1124\/dmd.30.11.1250","article-title":". Involvement of multiple UDP-glucuronosyltransferase 1A isoforms in glucuronidation of 5-(4-hydroxyphenyl)-5-phenylhydantoin in human liver microsomes.","volume":"30","author":"Nakajima","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"R143-2-20210129","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00007691-198309000-00014","article-title":"Monitoring phenytoin salivary and plasma utrafiltrates of pediatric patients.","volume":"5","author":"Bachmann","year":"1983","journal-title":"Ther Drug Monit"},{"key":"R144-2-20210129","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/j.1471-0528.1986.tb07827.x","article-title":"Phenytoin kinetics during pregnancy and the puerperium.","volume":"93","author":"Knott","year":"1986","journal-title":"Br J Obstet Gynaecol"},{"key":"R145-2-20210129","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00007691-199007000-00006","article-title":"Monitoring phenytoin therapy using citric acid-stimulated saliva in infants and children.","volume":"12","author":"Lifshitz","year":"1990","journal-title":"Ther Drug Monit"},{"issue":"suppl 3","key":"R146-2-20210129","first-page":"S172","article-title":"Correlation between serum and salivary phenytoin concentrations in Thai epileptic children.","volume":"94","author":"Liamsuwan","year":"2011","journal-title":"J Med Assoc Thai"},{"key":"R147-2-20210129","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/BF00196118","article-title":"Effect of saliva flow rate on saliva phenytoin concentrations: implications for therapeutic monitoring.","volume":"46","author":"Kamali","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"key":"R148-2-20210129","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.0013-9580.2004.455003.x","article-title":"Pregabalin pharmacology and its relevance to clinical practice.","volume":"45","author":"Ben-Menachem","year":"2004","journal-title":"Epilepsia"},{"key":"R149-2-20210129","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s13181-010-0052-3","article-title":". Significant pregabalin toxicity managed with supportive care alone.","volume":"6","author":"Wood","year":"2010","journal-title":"J Med Toxicol"},{"key":"R150-2-20210129","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/WNL.22.11.1186","article-title":"Metabolic disposition of primidone and its metabolites in epileptic subjects after single and repeated administration.","volume":"22","author":"Gallagher","year":"1972","journal-title":"Neurology"},{"key":"R151-2-20210129","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1528-1157.1979.tb04824.x","article-title":"Flow-dependent salivary primidone levels in epileptic children.","volume":"20","author":"Bartels","year":"1979","journal-title":"Epilepsia"},{"key":"R152-2-20210129","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1067\/mcp.2003.12","article-title":". Effects of age and sex on the disposition of retigabine.","volume":"73","author":"Hermann","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"R153-2-20210129","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/00912700222011210","article-title":". Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers.","volume":"42","author":"Ferron","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"R154-2-20210129","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1528-1167.2008.01665.x","article-title":". Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.","volume":"49","author":"Perucca","year":"2008","journal-title":"Epilepsia"},{"key":"R155-2-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1535-7511.2009.01336.x","article-title":"Rufinamide: a novel broad-spectrum antiepileptic drug.","volume":"10","author":"Wheless","year":"2010","journal-title":"Epilepsy Curr"},{"key":"R156-2-20210129","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/(SICI)1099-081X(199805)19:4<259::AID-BDD98>3.0.CO;2-V","article-title":". The influence of food on the disposition of the antiepileptic rufinamide in healthy volunteers.","volume":"19","author":"Cardot","year":"1998","journal-title":"Biopharm Drug Dispos"},{"key":"R157-2-20210129","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.nurt.2006.11.006","article-title":"Rufinamide.","volume":"4","author":"Arroyo","year":"2007","journal-title":"Neurotherapeutics"},{"issue":"suppl 6","key":"R158-2-20210129","first-page":"166","article-title":". Pharmacokinetics and safety of adjunctive rufinamide therapy in pediatric patients with epilepsy.","volume":"39","author":"Sachdeo","year":"1998","journal-title":"Epilepsia"},{"key":"R159-2-20210129","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.nurt.2006.10.001","article-title":"Stiripentol.","volume":"4","author":"Chiron","year":"2007","journal-title":"Neurotherapeutics"},{"key":"R160-2-20210129","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/clpt.1984.237","article-title":". Stiripentol kinetics in epilepsy: nonlinearity and interactions.","volume":"36","author":"Levy","year":"1984","journal-title":"Clin Pharmacol Ther"},{"key":"R161-2-20210129","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/j.1552-4604.1983.tb01799.x","article-title":". Pharmacokinetics of stiripentol in normal man: evidence of nonlinearity.","volume":"23","author":"Levy","year":"1983","journal-title":"J Clin Pharmacol"},{"key":"R162-2-20210129","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S0090-9556(25)08990-1","article-title":"The metabolic fate of stiripentol in man.","volume":"14","author":"Moreland","year":"1986","journal-title":"Drug Metab Dispos"},{"key":"R163-2-20210129","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1528-1157.1993.tb02416.x","article-title":". Stiripentol in atypical absence seizures in children: an open trial.","volume":"34","author":"Farwell","year":"1993","journal-title":"Epilepsia"},{"key":"R164-2-20210129","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","article-title":". Stiripentol in severe myoclonic epilepsy in infancy: a randomized placebo-controlled syndrome-dedicated trial.","volume":"356","author":"Chiron","year":"2000","journal-title":"Lancet"},{"key":"R165-2-20210129","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1528-1157.1995.tb02575.x","article-title":"Pharmacokinetics of tiagabine, a -amino butyric acid-uptake inhibitor, in healthy subjects after single and multiple doses.","volume":"36","author":"Gustavson","year":"1995","journal-title":"Epilepsia"},{"key":"R166-2-20210129","first-page":"225","article-title":"The pharmacokinetic profile of tiagabine.","volume":"12","author":"Wang","year":"2002","journal-title":"Rev Contemp Pharmacother"},{"key":"R167-2-20210129","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/archneur.55.1.56","article-title":". Tiagabine for complex partial seizures. A randomized, add-on, dose-response trial.","volume":"55","author":"Uthman","year":"1998","journal-title":"Arch Neurol"},{"key":"R168-2-20210129","first-page":"155","article-title":"The pharmacokinetic profile of topiramate.","volume":"10","author":"Patsalos","year":"1999","journal-title":"Rev Contemp Pharmacother"},{"key":"R169-2-20210129","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1528-1157.1996.tb00651.x","article-title":". Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy.","volume":"37","author":"Sachdeo","year":"1996","journal-title":"Epilepsia"},{"key":"R170-2-20210129","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.0013-9580.2005.55204.x","article-title":". Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine.","volume":"46","author":"Britzi","year":"2005","journal-title":"Epilepsia"},{"key":"R171-2-20210129","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/00007691-198612000-00005","article-title":". Variable free and total valproic acid concentrations in sole- and multi-drug therapy.","volume":"8","author":"Cramer","year":"1986","journal-title":"Ther Drug Monit"},{"key":"R172-2-20210129","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1365-2125.1978.tb01663.x","article-title":". Disposition of sodium valproate in epileptic patients.","volume":"5","author":"Perucca","year":"1978","journal-title":"Br J Clin Pharmacol"},{"key":"R173-2-20210129","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000457481","article-title":"Salivary excretion of drugs in children: theoretical and practical issues in therapeutic drug monitoring.","volume":"19","author":"Gorodischer","year":"1992","journal-title":"Dev Pharmacol Ther"},{"key":"R174-2-20210129","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0378-4347(00)80396-5","article-title":". Valproic acid analysis in saliva and serum using selected monitoring (electron ionization) of the tert-butyldimethylsilyl derivatives.","volume":"227","author":"Abbott","year":"1982","journal-title":"J Chromatogr"},{"key":"R175-2-20210129","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0022-3476(82)80490-3","article-title":"Saliva and serum valproic acid levels in epileptic children letter.","volume":"100","author":"Fung","year":"1982","journal-title":"J Pediatr"},{"key":"R176-2-20210129","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1528-1157.1982.tb05063.x","article-title":"The pharmacokinetics of valproic acid after oral and parenteral administration in healthy volunteers.","volume":"23","author":"Nitsche","year":"1982","journal-title":"Epilepsia"},{"key":"R177-2-20210129","doi-asserted-by":"crossref","first-page":"2S7","DOI":"10.1177\/0883073891006002031","article-title":"Pharmacology and clinical pharmacology of vigabatrin.","volume":"6","author":"Richens","year":"1991","journal-title":"J Child Neurolol"},{"key":"R178-2-20210129","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/clpt.1988.194","article-title":". Pharmacokinetics of vigabatrin: implications of creatinine clearance.","volume":"44","author":"Haegele","year":"1988","journal-title":"Clin Pharmacol Ther"},{"key":"R179-2-20210129","first-page":"447","article-title":"The pharmacology and pharmacokinetics of vigabatrin.","volume":"6","author":"Patsalos","year":"1995","journal-title":"Rev Contemp Pharmacother"},{"key":"R180-2-20210129","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/j.1528-1157.1992.tb02202.x","article-title":". Gamma-vinyl-GABA (vigabatrin): relationship between dosage, plasma concentrations, platelet GABA-transaminase inhibition, and seizure reduction in children.","volume":"33","author":"Arteaga","year":"1992","journal-title":"Epilepsia"},{"key":"R181-2-20210129","first-page":"1581","article-title":". Pharmacokinetic studies of AD-810, a new antiepileptic compound.","volume":"32","author":"Ito","year":"1982","journal-title":"Arzneimittelforschung"},{"key":"R182-2-20210129","first-page":"961","article-title":". Absorption, distribution and excretion of 3-(sulfamoyl14Cmethyl)-1,2-benziosoxazole (AD-810) in rats, dogs and monkeys and of AD-810 in men.","volume":"33","author":"Matsumoto","year":"1983","journal-title":"Arzneimittelfoeschung"},{"issue":"suppl 5","key":"R183-2-20210129","first-page":"172","article-title":". Single- and multiple-dose pharmacokinetics of zonisamide.","volume":"37","author":"Buchanan","year":"1996","journal-title":"Epilepsia"},{"key":"R184-2-20210129","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/j.1552-4604.1998.tb04406.x","article-title":". Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures.","volume":"38","author":"Kochak","year":"1998","journal-title":"J Clin Pharmacol"},{"key":"R185-2-20210129","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/00007691-199812000-00001","article-title":"Clinical pharmacology and therapeutic drug monitoring of zonisamide.","volume":"20","author":"Mimaki","year":"1998","journal-title":"Ther Drug Monit"},{"key":"R186-2-20210129","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/01.ftd.0000171869.56817.ae","article-title":". Stability of salivary concentrations of the newer antiepileptic drugs in the postal system.","volume":"27","author":"Jones","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R187-2-20210129","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2125.1978.tb01685.x","article-title":"Compliance with anticonvulsant therapy in a hospital clinic and community.","volume":"6","author":"Mucklow","year":"1978","journal-title":"Br J Clin Pharmacol"},{"key":"R188-2-20210129","first-page":"150","article-title":"Non-compliance with anticonvulsant therapy as a cause of seizures.","volume":"98","author":"Stanaway","year":"1985","journal-title":"N Z Med J"},{"key":"R189-2-20210129","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1469-8749.1981.tb08447.x","article-title":". Phenytoin therapy for epileptic children: evaluation of salivary and plasma concentrations and methods of assessing compliance.","volume":"23","author":"Zysset","year":"1981","journal-title":"Dev Med Child Neurol"},{"key":"R190-2-20210129","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1528-1157.1993.tb02393.x","article-title":". Carbamazepine and lamotrigine in healthy volunteers: relevance to early tolerance and clinical trial dosage.","volume":"34","author":"Hamilton","year":"1993","journal-title":"Epilepsia"},{"key":"R191-2-20210129","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1902\/jop.1996.67.6.597","article-title":". Plasma and saliva concentrations of phenytoin and 5-(4-hydroxyphenyl)-5-phenylhydantoin in relation to the incidence and severity of phenytoin-induced gingival overgrowth in epileptic patients.","volume":"67","author":"Ball","year":"1996","journal-title":"J Periodontol"},{"key":"R192-2-20210129","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1528-1157.1990.tb05360.x","article-title":". Effects of carbamazepine on psychomotor performance in children as a function of drug concentration, seizure type, and time of medication.","volume":"31","author":"Aman","year":"1990","journal-title":"Epilepsia"},{"key":"R193-2-20210129","first-page":"643","article-title":". Prevalence of toxic anticonvulsant drug concentrations in mentally retarded persons with epilepsy.","volume":"90","author":"Aman","year":"1986","journal-title":"Am J Ment Defic"},{"key":"R194-2-20210129","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2298\/VSP1205389D","article-title":". Toxicokinetics and correlation of carbamazepine salivary and serum concentrations in acute poisoning.","volume":"69","author":"Djordjevic","year":"2012","journal-title":"Vosjnosanit Pregl"},{"key":"R195-2-20210129","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00003088-200645040-00002","article-title":"Clinical pharmacokinetics of new generation antiepileptic drugs at the extremes of age.","volume":"45","author":"Perucca","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"R196-2-20210129","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0387-7604(94)90108-2","article-title":"Role of therapeutic drug monitoring (TDM) in pediatric anti-convulsant drug dosing.","volume":"16","author":"Walson","year":"1994","journal-title":"Brain Dev"},{"key":"R197-2-20210129","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1586\/14737175.7.2.179","article-title":"Antiepileptic drug treatment in children.","volume":"7","author":"Hadjiloizou","year":"2007","journal-title":"Exp Rev Neurother"},{"key":"R198-2-20210129","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00007691-198103000-00008","article-title":". Monitoring of phenobarbitone and phenytoin therapy in small children by salivary samples.","volume":"3","author":"Mucklow","year":"1981","journal-title":"Ther Drug Monit"},{"key":"R199-2-20210129","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00007691-199302000-00005","article-title":"Free phenytoin monitoring in serum and saliva of patients in China.","volume":"15","author":"Cai","year":"1993","journal-title":"Ther Drug Monit"},{"key":"R200-2-20210129","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00007691-200106000-00011","article-title":". Use of saliva in therapeutic drug monitoring of caffeine in preterm infants.","volume":"23","author":"de Wildt","year":"2001","journal-title":"Ther Drug Monit"},{"key":"R201-2-20210129","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2165\/00003088-200544100-00001","article-title":"Pregnancy-related changes in pharmacokinetics: a mechanistic-based approach.","volume":"44","author":"Anderson","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"R202-2-20210129","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0163-7258(87)90096-9","article-title":"Drug metabolism in pregnancy, infancy and childhood.","volume":"34","author":"Perucca","year":"1987","journal-title":"Pharmacol Ther"},{"issue":"suppl 2","key":"R203-2-20210129","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1212\/WNL.61.6_suppl_2.S35","article-title":"Antiepileptic drug pharmacokinetics during pregnancy and lactation.","volume":"61","author":"Pennell","year":"2003","journal-title":"Neurology"},{"key":"R204-2-20210129","first-page":"227","article-title":"Value of saliva anticonvulsant monitoring in pregnancy and the newborn.","volume":"27","author":"Knott","year":"1989","journal-title":"J Clin Chem Clin Biochem"},{"key":"R205-2-20210129","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archfami.3.7.589","article-title":"Antiepileptics in the elderly. Pharmacoepidemiology and pharmacokinetics.","volume":"3","author":"Cloyd","year":"1994","journal-title":"Arch Fam Med"},{"key":"R206-2-20210129","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/ageing\/10.2.73","article-title":"Drug response in the elderly: sensitivity and pharmacokinetic considerations.","volume":"10","author":"Crooks","year":"1981","journal-title":"Age Ageing"},{"key":"R207-2-20210129","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-198712010-00004","article-title":"Plasma protein binding of drugs in the elderly.","volume":"12","author":"Wallace","year":"1987","journal-title":"Clin Pharmacokinet"},{"key":"R208-2-20210129","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1365-2125.1986.tb02965.x","article-title":". The effect of age on carbamazepine pharmacokinetics and adverse effects.","volume":"22","author":"Hockings","year":"1986","journal-title":"Br J Clin Pharmacol"},{"key":"R209-2-20210129","first-page":"59","article-title":"Comparison of total, free, and salivary phenytoin concentrations in geriatric patients.","volume":"5","author":"Umstead","year":"1986","journal-title":"Clin Pharm"},{"key":"R210-2-20210129","first-page":"54","article-title":"Salivary phenytoin concentrations in geriatric patients.","volume":"1","author":"Umstead","year":"1982","journal-title":"Clin Pharm"},{"key":"R211-2-20210129","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3109\/00365517209102760","article-title":". Sequential changes of plasma proteins after surgical trauma.","volume":"29","author":"Aronsen","year":"1972","journal-title":"Scand J Clin Lab Invest Suppl"},{"key":"R212-2-20210129","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0022-3565(25)32025-2","article-title":". Phenytoin pharmacokinetics in burned rats and plasma protein binding of phenytoin in burned patients.","volume":"213","author":"Bowdle","year":"1980","journal-title":"J Pharmacol Exp Ther"},{"key":"R213-2-20210129","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/clpt.1984.73","article-title":"Plasma protein binding of drugs after severe burn injury.","volume":"35","author":"Martyn","year":"1984","journal-title":"Clin Pharmacol Ther"},{"key":"R214-2-20210129","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/00007691-199412000-00015","article-title":". Therapeutic drug monitoring of phenytoin in patients with acquired immunodeficiency syndrome.","volume":"16","author":"Burger","year":"1994","journal-title":"Ther Drug Monit"},{"issue":"suppl 8","key":"R215-2-20210129","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1528-1157.2001.0420s8018.x","article-title":"Elderly patients with systemic disease.","volume":"42","author":"Boggs","year":"2001","journal-title":"Epilepsia"},{"issue":"suppl 1","key":"R216-2-20210129","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/00003088-198400091-00009","article-title":"Free level monitoring of antiepileptic drugs. Clinical usefulness and case studies.","volume":"9","author":"Perucca","year":"1984","journal-title":"Clin Pharmacokinet"},{"issue":"suppl 1","key":"R217-2-20210129","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1111\/j.1528-1157.1982.tb06092.x","article-title":"Use of antiepileptic drugs in the presence of liver and kidney diseases: a review.","volume":"23","author":"Asconape","year":"1982","journal-title":"Epilepsia"},{"key":"R218-2-20210129","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/0731-7085(95)01303-3","article-title":". Assay of paracetamol and its metabolites in urine, plasma and saliva of children with chronic liver disease.","volume":"13","author":"Al-Obaidy","year":"1995","journal-title":"J Pharm Biomed Anal"},{"key":"R219-2-20210129","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(03)00409-5","article-title":"Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs.","volume":"2","author":"Patsalos","year":"2003","journal-title":"Lancet Neurol"},{"key":"R220-2-20210129","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S1474-4422(03)00483-6","article-title":"Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs.","volume":"2","author":"Patsalos","year":"2003","journal-title":"Lancet Neurol"},{"key":"R221-2-20210129","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1528-1157.2002.13001.x","article-title":". The importance of drug interactions in epilepsy therapy.","volume":"43","author":"Patsalos","year":"2002","journal-title":"Epilepsia"},{"key":"R222-2-20210129","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/clpt.1980.26","article-title":"Effects of aspirin on salivary and serum phenytoin kinetics in healthy subjects.","volume":"27","author":"Paxton","year":"1980","journal-title":"Clin Pharmacol Ther"},{"key":"R223-2-20210129","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/clpt.1980.235","article-title":". Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects.","volume":"28","author":"Perucca","year":"1980","journal-title":"Clin Pharmacol Ther"},{"key":"R224-2-20210129","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1212\/WNL.31.4_Part_2.467","article-title":"Intravenous valproate: effects on plasma and saliva phenytoin levels.","volume":"31","author":"Pisani","year":"1981","journal-title":"Neurology"},{"key":"R225-2-20210129","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/clpt.1981.10","article-title":". Phenytoin-salicylate interaction.","volume":"29","author":"Leonard","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"R226-2-20210129","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/bmj.284.6308.13","article-title":"Phenytoin-valproate interaction: importance of saliva monitoring in epilepsy.","volume":"284","author":"Knott","year":"1982","journal-title":"Br Med J"},{"key":"R227-2-20210129","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2125.1983.tb01557.x","article-title":". Pharmacokinetic investigation of the interaction of azapropazone with phenytoin.","volume":"15","author":"Geaney","year":"1983","journal-title":"Br J Clin Pharmacol"},{"key":"R228-2-20210129","first-page":"207","article-title":". Single dose phenytoin clearance during erythromycin treatment.","volume":"46","author":"Bachmann","year":"1984","journal-title":"Res Commun Chem Pathol Pharmacol"},{"issue":"suppl 5","key":"R229-2-20210129","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1528-1167.2006.00871.x","article-title":". Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs.","volume":"47","author":"Perucca","year":"2006","journal-title":"Epilepsia"},{"key":"R230-2-20210129","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1212\/01.wnl.0000319958.37502.8e","article-title":"Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures.","volume":"71","author":"Berg","year":"2008","journal-title":"Neurology"},{"key":"R231-2-20210129","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1345\/aph.1P765","article-title":"Generic substitution of levetiracetam resulting in increased breakthrough seizures.","volume":"45","author":"Fitzgerald","year":"2011","journal-title":"Ann Pharmacother"},{"key":"R232-2-20210129","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0887-8994(87)90002-6","article-title":". The 24 hour variation of salivary carbamazepine and carbamazepine-10,11-epoxide concentrations in children with epilepsy.","volume":"3","author":"Backman","year":"1987","journal-title":"Pediatr Neurol"},{"key":"R233-2-20210129","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000138063","article-title":". Phenytoin as a probe of drug metabolism. Predicting clearance with a salivary sample.","volume":"30","author":"Bachmann","year":"1985","journal-title":"Pharmacology"},{"key":"R235-2-20210129","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.2042-7158.1985.tb03070.x","article-title":". A comparative study of the bioavailability of five different phenytoin preparations.","volume":"37","author":"Hirji","year":"1985","journal-title":"J Pharm Pharmacol"},{"key":"R236-2-20210129","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/bdd.728","article-title":". The use of saliva as a biological fluid in relative bioavailability studies: comparison and correlation with plasma results.","volume":"31","author":"Ruiz","year":"2010","journal-title":"Biopharm Drug Dispos"},{"key":"R237-2-20210129","first-page":"80","article-title":"Salivary antiepileptic drug levels in Thai children.","volume":"82","author":"Kankirawatana","year":"1999","journal-title":"J Med Assoc Thai"},{"key":"R239-2-20210129","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/00007691-199109000-00011","article-title":". Measurement of phenytoin and carbamazepine in an ultrafiltrate of saliva.","volume":"13","author":"Schramm","year":"1991","journal-title":"Ther Drug Monit"},{"key":"R240-2-20210129","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/clinchem\/37.1.114","article-title":"An ultrafiltrate of saliva collected in situ as a biological sample for diagnostic evaluation.","volume":"37","author":"Schramm","year":"1991","journal-title":"Clin Chem"},{"key":"R241-2-20210129","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/jat\/23.6.452","article-title":". Correlation of saliva codeine concentrations with plasma concentrations after oral codeine administration.","volume":"23","author":"ONeal","year":"1999","journal-title":"J Anal Toxicol"},{"key":"R242-2-20210129","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.forsciint.2005.02.028","article-title":"Oral fluid collection: the neglected variable in oral fluid testing.","volume":"150","author":"Crouch","year":"2005","journal-title":"Forensic Sci Int"},{"key":"R243-2-20210129","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00007691-198503000-00006","article-title":". Fallacious results from measuring salivary carbamazepine concentrations.","volume":"7","author":"Dickinson","year":"1985","journal-title":"Ther Drug Monit"},{"key":"R244-2-20210129","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S0140-6736(77)92097-9","article-title":"Drug formulation and salivary phenytoin measurements.","volume":"1","author":"Ayers","year":"1977","journal-title":"Lancet"},{"key":"R245-2-20210129","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007691-200406000-00013","article-title":". Feasibility and acceptance of salivary monitoring of antiepileptic drugs via the US Postal Service.","volume":"26","author":"Tennison","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R246-2-20210129","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/00007691-199410000-00001","article-title":". Saliva versus blood sampling for therapeutic drug monitoring in children: patient and parental preferences and economic analysis.","volume":"16","author":"Gorodischer","year":"1994","journal-title":"Ther Drug Monit"},{"key":"R247-2-20210129","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0887-8994(03)00410-7","article-title":"Physicians preference for antiepileptic drug concentration testing.","volume":"30","author":"Baumann","year":"2004","journal-title":"Pediatr Neurol"},{"key":"R248-2-20210129","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1017\/S0033291798007144","article-title":"The epidemiology of blood-injection-injury phobia.","volume":"28","author":"Bienvenu","year":"1998","journal-title":"Psychol Med"},{"key":"R249-2-20210129","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0378-4347(93)80477-L","article-title":". Simultaneous determination of carbamazepine, phenytoin, phenobarbital, primidone and their principal metabolites by high performance liquid chromatography with photodiode-array detection.","volume":"616","author":"Liu","year":"1993","journal-title":"J Chromatogr"},{"key":"R250-2-20210129","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cca.2006.06.022","article-title":". Determination of levetiracetam in human plasmaserumsaliva by liquid chromatography-electrospray tandem mass spectrometry.","volume":"375","author":"Guo","year":"2007","journal-title":"Clin Chim Acta"},{"key":"R251-2-20210129","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.aca.2009.12.030","article-title":"Liquid chromatographic analysis of oxcarbazepine and its metabolites in plasma and saliva after a novel microextraction by packed sorbent procedure.","volume":"661","author":"Saracino","year":"2010","journal-title":"Anal Chim Acta"},{"key":"R252-2-20210129","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2478\/v10007-012-0015-0","article-title":". Development and validation of bioanalytical LC-UV method with solid-phase extraction for determination of valproic acid in saliva.","volume":"62","author":"Tonic-Ribarrska","year":"2012","journal-title":"Acta Pharm"},{"key":"R253-2-20210129","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1212\/WNL.42.5.988","article-title":"Clinical utility of unbound antiepileptic drug blood levels in the management of epilepsy.","volume":"42","author":"Lenn","year":"1992","journal-title":"Neurology"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e31827c11e7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T15:50:18Z","timestamp":1745941818000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201302000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":247,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e31827c11e7","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}